NABRIVA THERAPEUTICS PLC (NBRV) Stock Price & Overview
NASDAQ:NBRV • IE000OZRGNV6
The current stock price of NBRV is 1.42 USD. Today NBRV is down by 0%. In the past month the price decreased by -5.96%. In the past year, price decreased by -69.25%.
NBRV Key Statistics
- Market Cap
- 4.546M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -18.63
- Dividend Yield
- N/A
NBRV Stock Performance
NBRV Stock Chart
NBRV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBRV. When comparing the yearly performance of all stocks, NBRV is a bad performer in the overall market: 92.64% of all stocks are doing better.
NBRV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBRV. Both the profitability and financial health of NBRV have multiple concerns.
NBRV Earnings
NBRV Forecast & Estimates
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of 49.57% and a revenue growth 89.23% for NBRV
NBRV Groups
Sector & Classification
NBRV Financial Highlights
Over the last trailing twelve months NBRV reported a non-GAAP Earnings per Share(EPS) of -18.63. The EPS increased by 20.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBRV Ownership
NBRV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.96 | 943.209B | ||
| JNJ | JOHNSON & JOHNSON | 20.78 | 585.582B | ||
| MRK | MERCK & CO. INC. | 22.4 | 287.316B | ||
| PFE | PFIZER INC | 9 | 155.235B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 122.147B | ||
| ZTS | ZOETIS INC | 16.31 | 50.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.88 | 26.934B | ||
| VTRS | VIATRIS INC | 5.5 | 16.085B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.56 | 11.659B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.158B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.518B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.968B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.91 | 4.412B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBRV
Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Company Info
IPO: 2015-09-18
NABRIVA THERAPEUTICS PLC
Alexandra House Office 225/227,, The Sweepstakes,, Ballsbridge
DUBLIN 19406 IE
CEO: Theodore Schroeder
Employees: 39
Phone: 3536108166640.0
NABRIVA THERAPEUTICS PLC / NBRV FAQ
What does NBRV do?
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Can you provide the latest stock price for NABRIVA THERAPEUTICS PLC?
The current stock price of NBRV is 1.42 USD.
Does NABRIVA THERAPEUTICS PLC pay dividends?
NBRV does not pay a dividend.
What is the ChartMill rating of NABRIVA THERAPEUTICS PLC stock?
NBRV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about NABRIVA THERAPEUTICS PLC (NBRV) stock?
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
What is the Price/Earnings (PE) ratio of NABRIVA THERAPEUTICS PLC (NBRV)?
NABRIVA THERAPEUTICS PLC (NBRV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.63).